A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

Inclusion Criteria: * Male or female between the ages of 4 and 40 * Pathologically confirmed Focal Cortical Dysplasia type II (FCDII) * Refractory seizure in spite of at least 2 antiepileptic drugs (AEDs) and surgery * Subjects must have experienced at least 3 seizure events per month for two months retrospectively among 3 months prior to the baseline period in spite of using 1 AED or more. * Must be at least one antiepileptic drug at a stable dose for at least 4 weeks at the start of the 4-week prospective baseline phase, remain on the same regimen throughout the baseline phase. * VNS and ketogenic diet are allowed. If the patient is using VNS, device stimulator parameters must remain constant throughout the baseline phase. If the patient is on ketogenic diet, the ratio of the diet must remain constant throughout the baseline phase. * At least 3 seizures throughout the baseline phase. * Subjects and their legal guardians must have the ability to comprehend the informed consent form and be willing to provide informed consent. For subjects who are too young or unable to comprehend the written consent, a legal guardian who is able to describe and provide an understanding of the informed consent to the subject must sign the consent form on behalf of the subject. Exclusion Criteria: * Patients who need hospitalization due to causes not related to FCDII or epilepsy * Patients who are pregnant or planning on becoming pregnant * Patients with seizures secondary to causes other th…